Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/16/20 | $115,000,000 | Series B |
Alexandria Venture Investments ArrowMark Partners Avidity Partners BlackRock Casdin Capital Cormorant Asset Management EcoR1 Capital  Janus Henderson Investors Redmile Group Samsara BioCapital | undisclosed |
